ADC Combined With Immunomodulators Active in R/R Myeloma

(MedPage Today) -- Indatuximab ravtansine (BT062) combined with immunomodulatory drugs showed antitumor activity in patients with relapsed or refractory multiple myeloma, according to results from a phase I/IIa study.
An objective response was...